ArticleBeyoglu eye journal2025
Selenium: Could It Be the Game-Changer for Ocular Surface and Anterior Chamber in Graves' Disease?
Article in Beyoglu eye journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the effects of selenium supplementation on ocular surface parameters and anterior segment architecture in euthyroid Graves' disease (GD) patients without ophthalmopathy. Methods: This cross-sectional study included 218 consecutive euthyroid GD patients without clinical manifestations of Graves' ophthalmopathy (GO). Patients underwent comprehensive ophthalmological examination, including the Ocular Surface Disease Index (OSDI) questionnaire, tear film break-up time (T-BUT), Oxford scale scoring, and Pentacam Scheimpflug imaging for anterior segment parameters assessment. Selenium intake was questioned, and based on selenium intake, participants were divided into two groups: the selenium intake group (n=106), receiving selenium supplementation (100 µg twice daily for 6 months) with standard anti-thyroid therapy, and the control group (n=112), receiving only standard anti-thyroid therapy. Results: The mean age was 45.7±7.8 years (range: 30-61) in the selenium intake group (n=106; 48 females, 58 males) and 46.1±7.5 years (range: 30-60) in the control group (n=112; 52 females, 60 males), with no significant difference between groups (p=0.821 for age, p=0.904 for gender distribution). The mean duration of selenium supplementation was 11.4±4.2 months. The selenium group showed significantly better ocular surface parameters, with lower OSDI scores and higher T-BUT values compared to the control group (p<0.001 for both). Oxford staining scores were lower in the selenium group, though not statistically significant (p=0.244). Pentacam analysis revealed significantly higher anterior chamber volume (p=0.024) and central corneal thickness (p<0.001) in the selenium group, while anterior chamber depth and angle width were higher but not statistically significant (p=0.322 and p=0.276, respectively). Conclusion: Selenium supplementation is associated with better ocular surface parameters and different anterior segment architecture in euthyroid GD patients without ophthalmopathy. Clinical associations observed in these cases may be related to selenium's antioxidant and anti-inflammatory properties through glutathione peroxidase and thioredoxin reductase activity, suggesting selenium as a potentially beneficial therapeutic approach for ocular surface integrity in GD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.